hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06317714, orgStudyIdInfo id: IR-2023/0002, secondaryIdInfos id: 2023-A02233-42, type: OTHER, domain: ANSM, briefTitle: Long-term Follow-up and Quality of Life of Patients Treated With Anticancer Drugs, acronym: THERAPINNOV, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2027-03-08, completionDateStruct date: 2027-03-08, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Institut Rafael, class: OTHER, descriptionModule briefSummary: Currently, aspects related to the effects of anticancer treatments and the quality of life of patients and their needs are still poorly documented at the Rafael Institute. Thus this study will meet a dual objective: (1) the establishment of a registry to collect data on the safety and effectiveness of innovative and expensive anticancer drugs when administered in real life and (2) a measurement quantitative quality of life of patients treated with these drugs., conditionsModule conditions: Oncology, conditions: Quality of Life, conditions: Symptoms and Signs, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: questionnaires, outcomesModule primaryOutcomes measure: overall survival, primaryOutcomes measure: progression free survival, primaryOutcomes measure: incidence of adverse events, primaryOutcomes measure: incidence of serious adverse events, secondaryOutcomes measure: Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire Core 30 (QLQ-C30) Score, secondaryOutcomes measure: change from baseline in quality of life measured with the EQ5D5L questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute Rafaël, status: RECRUITING, city: Levallois Perret, state: Institut Rafael, zip: 92300, country: France, contacts name: Alain Toledano, role: CONTACT, phone: 33 (0)1 47 58 05 96, geoPoint lat: 48.89389, lon: 2.28864, hasResults: False
protocolSection identificationModule nctId: NCT06317701, orgStudyIdInfo id: IRB23-1801, briefTitle: Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-04, primaryCompletionDateStruct date: 2028-04, completionDateStruct date: 2028-04, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University of Chicago, class: OTHER, descriptionModule briefSummary: The purpose of this study is to determine if the treatment of Obstructive sleep apnea (OSA) by hypoglossal nerve stimulation (HGNS) will alter glucose metabolism. The study team will also determine if the treatment of Obstructive sleep apnea (OSA) by (hypoglossal nerve stimulation) HGNS will alter predictors of cardiovascular outcomes., conditionsModule conditions: Obstructive Sleep Apnea, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Hypoglossal Nerve Stimulation (HGNS), outcomesModule primaryOutcomes measure: Glycemic variability, primaryOutcomes measure: Mean systolic BP (daytime and nocturnal), primaryOutcomes measure: Glycemic variability, secondaryOutcomes measure: mean blood glucose levels, secondaryOutcomes measure: mean ambulatory glucose excursions, secondaryOutcomes measure: time blocks, secondaryOutcomes measure: Morning fasting insulin, including calculated insulin resistance (HOMA-IR), secondaryOutcomes measure: Mean norepinephrine levels, secondaryOutcomes measure: Morning fasting blood glucose, secondaryOutcomes measure: Hemoglobin A1c, secondaryOutcomes measure: Insulin levels, secondaryOutcomes measure: c-peptide levels, secondaryOutcomes measure: fasting lipid profile (triglycerides), secondaryOutcomes measure: heart rate indices by activity monitor, secondaryOutcomes measure: sympathetic activity by plasma norepinephrine, secondaryOutcomes measure: Morning fasting insulin of c-peptide level, secondaryOutcomes measure: fasting lipid profile (HDL- cholesterol), secondaryOutcomes measure: fasting lipid profile ( LDL-cholesterol), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The University of Chicago, status: RECRUITING, city: Chicago, state: Illinois, zip: 60637, country: United States, contacts name: Phillip LoSavio, MD, MS, role: CONTACT, phone: 773-702-5189, email: Phillip.Losavio@bsd.uchicago.edu, contacts name: Leila Yazdanbakhsh, role: CONTACT, phone: 773-834-5087, email: leila.yazdanbakhsh@bsd.uchicago.edu, contacts name: Phillip LoSavio, MD, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06317688, orgStudyIdInfo id: TWU IRB-FY2023-157, briefTitle: Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-11-06, primaryCompletionDateStruct date: 2024-08-14, completionDateStruct date: 2024-08-14, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Texas Woman's University, class: OTHER, collaborators name: Harris Health System (Houston, Texas), descriptionModule briefSummary: Problem of the Study This study was designed to test the effectiveness of the application of extra-virgin coconut oil versus Highly Purified Anhydrous (HPA) Lanolin in ameliorating nipple pain, cracking and eventually the prevention of subacute lactation mastitis in breastfeeding women. It is theorized that the nipple crack, nipple pain are early warning signs of subacute clinical lactation mastitis. Goal is after application of extra-virgin coconut oil comparative analysis will be done at one week, three weeks, and six weeks. These complications associated with development of subacute mastitis can be addressed early during the first six weeks of lactation., conditionsModule conditions: Lactation Mastitis, conditions: Breast Feeding, conditions: Staphylococcus Aureus Infection, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized Control Trial- Random Assignment-Random Selection, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Extra-Virgin Coconut Oil, outcomesModule primaryOutcomes measure: Measurement of change in pain level (Numeric Pain Rating Scale McCaffery, 1989), primaryOutcomes measure: Measurement of Development of Nipple Crack (Nipple Tenderness Scale Storr 1988), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Harris Health System, city: Houston, state: Texas, zip: 77030, country: United States, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06317675, orgStudyIdInfo id: ct9873, briefTitle: Osteopathic Manipulative Treatment for Gastro-oesophageal Reflux Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-18, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Studio Osteopatico Busto Arsizio, class: OTHER, descriptionModule briefSummary: To evaluate the effects of osteopathic manipulative treatment in patients affected by symptoms related to gastro-oesophageal reflux disease (GERD), conditionsModule conditions: Gastro-oesophageal Reflux Disease, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Osteopathic manipulative treatment (OMT), outcomesModule primaryOutcomes measure: Mean change in GERD-HRQL, primaryOutcomes measure: Adverse effects, secondaryOutcomes measure: Exercise adherence, secondaryOutcomes measure: Change in drugs use, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CTFO, status: RECRUITING, city: Saronno, state: Varese, zip: 21047, country: Italy, contacts name: +39 02 96701013, role: CONTACT, geoPoint lat: 45.62513, lon: 9.03517, hasResults: False
protocolSection identificationModule nctId: NCT06317649, orgStudyIdInfo id: NCI-2024-01987, secondaryIdInfos id: NCI-2024-01987, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: MM1OA-EA02, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: MM1OA-EA02, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2025-10-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach., conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 147, type: ESTIMATED, armsInterventionsModule interventions name: Azacitidine, interventions name: Biospecimen Collection, interventions name: Bone Marrow Aspiration, interventions name: Bone Marrow Biopsy, interventions name: Gilteritinib, interventions name: Venetoclax, outcomesModule primaryOutcomes measure: Rate of measured residual disease (MRD) negative complete remission (CR), secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Event-free survival, secondaryOutcomes measure: Incidence of adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06317636, orgStudyIdInfo id: 73487, briefTitle: Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression, acronym: PEAK, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare ketamine to a placebo when given as a single infusion during sedation in adults with chronic pain and depression. This study aims to:* Evaluate whether ketamine is more effective than a placebo in treating chronic pain and depression* Confirm that propofol sedation is a safe way to keep participants blinded to treatment* Assess patients' comfort with the sedation process to improve future studies* Explore whether patient expectations affects their pain and depressionParticipants will:* Need to qualify for the study based on stringent medical criteria* Undergo sedation with propofol* Randomly receive either a ketamine or a placebo (saline) infusion during sedation* Complete several study assessments over 5-7 weeks, conditionsModule conditions: Chronic Pain, conditions: Depression, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Ketamine, interventions name: Normal saline, outcomesModule primaryOutcomes measure: Pain Intensity (past 24 hours), secondaryOutcomes measure: Depression severity, secondaryOutcomes measure: Pain Intensity (current), otherOutcomes measure: Number and severity of adverse events related to sedation, otherOutcomes measure: Proportion of participants who accurately recall intra-sedation events, otherOutcomes measure: Treatment guess, otherOutcomes measure: Treatment expectancies, otherOutcomes measure: Pain interference, otherOutcomes measure: Physical function, otherOutcomes measure: Number of painful body regions, otherOutcomes measure: Change in pain medication utilization, otherOutcomes measure: Pressure pain threshold, otherOutcomes measure: Enrollment rate, otherOutcomes measure: Consent fraction, otherOutcomes measure: Participant Experience Survey, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06317623, orgStudyIdInfo id: 0292/21/2023-00590, briefTitle: Urinary Tract Dilations in Prenatal and Postnatal Life, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: SonoClinic, class: NETWORK, descriptionModule briefSummary: The goals of this study are to use a questionnaire survey to determine the state of awareness of the diagnosis and management of patients with urinary tract dilation across several medical professionals, to predict the severity of the postnatal course and surgical intervention in fetuses with urinary tract dilation detected during pregnancy, and to create a model of prenatal and postnatal care for patients with dilation of the urinary tract for multidisciplinary use., conditionsModule conditions: Urinary Tract Dilatation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Prenatal and postnatal ultrasound examination, outcomesModule primaryOutcomes measure: The goal is the prediction of severe postnatal course and surgical intervention in fetuses with dilatation of the urinary tract according to the UTD classification created in 2014., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Svetlana Jánošová, status: RECRUITING, city: Záborské, zip: 08253, country: Slovakia, contacts name: Svetlana Jánošová, role: CONTACT, phone: +421908369470, email: svetlana.janosova@gmail.com, contacts name: Róbert Dankovčík, role: CONTACT, phone: +4219051291297, email: dankovcik@gmail.com, geoPoint lat: 48.9451, lon: 21.28977, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2023-12-19, uploadDate: 2024-02-26T14:43, filename: Prot_000.pdf, size: 1211102, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2023-12-19, uploadDate: 2024-02-26T14:43, filename: ICF_001.pdf, size: 373557, hasResults: False
protocolSection identificationModule nctId: NCT06317610, orgStudyIdInfo id: CQGOG0206, briefTitle: Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Chongqing University Cancer Hospital, class: OTHER, descriptionModule briefSummary: The present study aims to collect early bright field image of patient-derived organoids with ovarian cancer. By leveraging artificial intelligence, this study will seek to construct and refine algorithms that able to predict growth of ovarian cancer organoids., conditionsModule conditions: Ovarian Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI, outcomesModule primaryOutcomes measure: AUC of growth prediction performance using deep learning model, primaryOutcomes measure: Accuracy of growth prediction using deep learning model, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chongqing Cancer Hospital, status: RECRUITING, city: Chongqing, state: Chongqing, zip: 400030, country: China, contacts name: Dongling Zou, M.D., role: CONTACT, phone: 13657690699, email: cqzl_zdl@163.com, contacts name: Dongling Zou, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06317597, orgStudyIdInfo id: OSS2024-0311, briefTitle: Efficacy of Short Time Intervals in Split-Dose Bowel Preparation of Oral Sulfate Solution for Colonoscopy, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Changhai Hospital, class: OTHER, collaborators name: Peking University People's Hospital, collaborators name: Internet Hospital of Tianjin Medical University General Hospital, collaborators name: The Affiliated Suzhou Hospital of Nanjing Medical University, collaborators name: Tianjin First Central Hospital, collaborators name: Tianjin Beichen Hospital, collaborators name: ShangDong Provincial Hospital, collaborators name: The Affiliated Hospital of Qingdao University, collaborators name: First People's Hospital of Hangzhou, collaborators name: The Third People's Hospital of Chengdu, collaborators name: Ningbo Yinzhou District Second Hospital, collaborators name: Changshu Affiliated Hospital of Soochow University, collaborators name: Linyi People's Hospital, collaborators name: Shanghai East Hospital, collaborators name: Heilongjiang Province Hospital Nangang Branch, collaborators name: The Affiliated Jiangyin Hospital of Nantong University, collaborators name: West China Hospital, descriptionModule briefSummary: To evaluate whether oral sulfate solution administered in a short time interval (6-8 hours) between the first and last dose of laxative is not inferior to a long time interval (10-12 hours) in bowel preparation quality., conditionsModule conditions: Colonoscopy: Bowel Preparation, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: TRIPLE, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 448, type: ESTIMATED, armsInterventionsModule interventions name: Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution, interventions name: Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution, outcomesModule primaryOutcomes measure: Bowel preparation adequate rate, secondaryOutcomes measure: Acceptability of bowel preparation by questionnaire survey, otherOutcomes measure: Incidence of laxative-related adverse events assessed by clinical examinations, otherOutcomes measure: Colonoscopy completion rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Changhai Hospital, city: Shanghai, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False